Yolanda Vea, MD
Vascular Surgery · Vancouver, WANPI 1588826176
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Medtronic at 47.1% of the total. Reporting peaked in 2019 at $1,890 and has fallen 95.6% since, to $84 in 2025.
Across 68 payments — averaging $80.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Silk Road Medical, Inc.$2K
- W. L. Gore & Associates, Inc.$242
- Johnson & Johnson$208
- Bolton Medical Inc$137
- Penumbra, Inc.$126
- plus $554 from 13 others
What the payments were for
- Speaking & faculty fees$1,18822%
- Travel & lodging$1,04219%
- Food & beverage$3,25259%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $2,580 |
| Silk Road Medical, Inc. | 12 | $1,633 |
| W. L. Gore & Associates, Inc. | 4 | $242 |
| Johnson & Johnson | 6 | $208 |
| Bolton Medical Inc | 1 | $137 |
| Penumbra, Inc. | 1 | $126 |
| Abbott | 2 | $115 |
| Solventum Corporation | 4 | $91 |
| Cardiovascular Systems Inc. | 4 | $73 |
| Boston Scientific | 2 | $47 |
| Shockwave Medical, Inc | 2 | $40 |
| Avita Medical Americas, LLC | 1 | $32 |
| Terumo Medical Corporation | 1 | $28 |
| Convatec Inc. | 1 | $27 |
| Organogenesis Inc. | 1 | $26 |
| Lemaitre Vascular, Inc. | 1 | $22 |
| Globus Medical | 1 | $21 |
| Artivion, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$2,611
- ENROUTE Transcarotid Stent$1,488
- ClosureFast$1,188
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$1,123
- Endurant$500
- ENHANCE Transcarotid Peripheral Access Kit$365
- ENROUTE .014 Guidewire$365
- ENDURANT IIS$148
- Abre$144
- TREO ABDOMINAL STENT-GRAFT SYSTEM$137
- Penumbra System$126
- GORE TAG Thoracic Branch Endoprosthesis$116
- Valiant Captivia$114
How this compares
$5,481 in reported general payments places this provider in the 55th percentile of 111 vascular surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 33 | $26,418 |
| ClopidogrelClopidogrel Bisulfate | 91 | $806 |
| Cilostazol | 27 | $510 |
| Oxycodone Hcl | 48 | $145 |
| Gabapentin | 12 | $103 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $208 | $26,41833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 vascular surgery providers in Washington.
Other vascular surgery in Vancouver
- Carber HuangVancouver$8K
- Benjamin StarnesSeatle$666K
- Kathleen GibsonBellevue$593K
- Brian FerrisBellevue$170K
- Sara ZettervallSeattle$126K
- Paul HayesSeattle$83K
- Elina QuirogaSeattle$69K
- Lorena de Marco GarciaYakima$60K
- Mark MeissnerSeattle$43K
- Stephen MurraySpokane$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.